Blood test could revolutionize colorectal cancer Follow-Up
NCT ID NCT05904665
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This study tests whether a blood test that detects tumor DNA (ctDNA) can find colorectal cancer recurrence earlier than standard methods like CEA blood tests or CT scans. Researchers will follow 584 patients with stage I-III colorectal cancer after surgery, monitoring ctDNA every three months for two years. The goal is to see if this approach leads to more patients receiving curative treatment when cancer returns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ctDNA methylation test (blood test)
What this could lead to
If successful, this blood test could help doctors catch cancer return earlier and guide more effective treatment, potentially improving survival.
What could go wrong
This is an early-stage study with 584 people, and the test may not prove better than current monitoring. False positives or negatives are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.